Shield Therapeutics PLC

Shield Therapeutics hails 'enormous' achievement of US regulatory approval

Shield Therapeutics PLC's (LON:STX) Carl Sterritt speaks to Proactive London's Andrew Scott after announcing they've passed a major milestone with US regulatory sign-off for its iron deficiency treatment.

The Food & Drug Administration has given what’s called broad label approval to Feraccru, which will be marketed as Accrufer in America.

Quick facts: Shield Therapeutics PLC

Price: £1.81

Market: LSE
Market Cap: £212.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019. ''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're...

2 weeks ago


Half-year Report

2 weeks, 1 day ago

Notice of Results

3 weeks, 1 day ago

Second Price Monitoring Extn

3 weeks, 6 days ago

Price Monitoring Extension

3 weeks, 6 days ago

Additional Listing

on 2/7/19

Result of AGM

on 13/6/19

2 min read